Non-small cell lung cancer
Summit Therapeutics Inc. focuses on advanced non-small cell lung cancer, including metastatic non-squamous NSCLC and disease that has progressed after prior systemic treatment. Its clinical portfolio includes patients with EGFR-mutant tumors and those whose cancer has advanced following EGFR tyrosine kinase inhibitor therapy.
- EGFR-mutant lung cancer
- Locally advanced NSCLC
- Metastatic non-squamous NSCLC
- Post-EGFR-TKI treatment resistance
The sponsor’s work in this area centers on treatment-resistant lung cancer populations with high unmet need.
Squamous lung cancer
The sponsor also studies metastatic squamous non-small cell lung cancer, a distinct histologic subtype of lung cancer with separate therapeutic considerations from non-squamous disease. This area reflects interest in advanced thoracic malignancies requiring systemic treatment options.
- Metastatic squamous NSCLC
- Thoracic oncology
- Advanced solid tumors
Research in this field aligns with broader oncology development in difficult-to-treat lung cancer subgroups.
Gastrointestinal oncology
Summit Therapeutics Inc. is active in metastatic colorectal cancer, extending its oncology program into gastrointestinal malignancy. The clinical focus includes first-line treatment settings for advanced colorectal disease.
- Metastatic colorectal cancer
- Gastrointestinal cancer
- First-line metastatic disease
This area adds coverage of a major solid-tumor indication beyond lung cancer.
Immuno-oncology and combination therapy
The sponsor’s trials include immuno-oncology approaches combined with established chemotherapy backbones, reflecting interest in treatment strategies for advanced solid tumors. This includes combinations with platinum-doublet chemotherapy and FOLFOX in cancer settings where systemic control remains a priority.
- Immuno-oncology combinations
- Platinum-based chemotherapy
- FOLFOX-based regimens
These research areas connect lung and colorectal cancer development through shared interest in combination treatment approaches.
